Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology.
Anterior chamber-associated immune deviation (ACAID), a manifestation of ocular immune privilege, prevents Th1-dependent delayed hypersensitivity from developing in response to eye-derived Ags, thereby preserving vision. Since Th2-type cells have recently been shown to mediate destructive inflammation of the cornea, we wondered whether pre-emptive induction of ACAID could inhibit Th2 responses. Using a murine model of OVA -specific, Th2-dependent pulmonary inflammation, we pretreated susceptible mice by injecting OVA alone into the anterior chamber, or by injecting OVA-pulsed, TGF-beta2-treated peritoneal exudate cells i.v. These mice were then immunized with OVA plus alum strategy that generates Th2-mediated OVA-specific pulmonary pathology. When pretreated mice were challenged intratracheally with OVA, their bronchoalveolar lavage fluids contained far fewer eosinophils and significantly less IL-4, IL-5, and IL-13 compared with that of positive, nonpretreated controls. Similarly, lung-draining lymph node cells of pretreated mice secreted significantly less IL-4, IL-5, and IL-13 when challenged in vitro with OVA. Moreover, sera from pretreated mice contained much lower titers of OVA-specific IgE Abs. We conclude that Ags injected into the anterior chamber of the eye impair both Th1 and Th2 responses. These results reduce the likelihood that ACAID regulates Th1 responses via a Th2-like mechanism. Thus, immune privilege of the eye regulates inflammation secondary to both Th1- and Th2-type immune responses.
Katagiri
Kazumoto
K
Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA.
Zhang-Hoover
Jie
J
Mo
Jun Song
JS
Stein-Streilein
Joan
J
Streilein
J Wayne
JW
D000818:Animals; D000867:Anterior Chamber / Q000276:immunology*; D002478:Cells, Cultured; D005122:Exudates and Transudates / Q000166:cytology / Q000276:immunology; D006968:Hypersensitivity, Delayed / Q000276:immunology / Q000473:pathology; D007108:Immune Tolerance / Q000276:immunology*; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007267:Injections; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007442:Intubation, Intratracheal; D008168:Lung / Q000276:immunology* / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage; D010537:Peritoneum / Q000166:cytology / Q000276:immunology; D012130:Respiratory Hypersensitivity / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D018418:Th2 Cells / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D053781:Transforming Growth Factor beta2
D007074:Immunoglobulin G; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D007073:Immunoglobulin E; D010047:Ovalbumin